Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
175
resultados
Última actualización
08/06/2025 [07:07:00]
Resultados 50 a 75 de 175
Resumen de: WO2025098545A1
The invention relates to small molecule inhibitors of formula (I) targeting the nsp14 protein of SARS- CoV-2 and other coronaviruses, for use as antiviral agents directly targeting viral proteins.
Resumen de: AU2023353862A1
The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants and other respiratory viruses that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protein, engineered nucleocapsid protein, engineered hemagglutinin protein, and/or engineered respiratory syncytial virus prefusion or fusion (RSV F) protein to the subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of spike-display, nucleocapsid-display, hemagglutinin-display, and/or RSV F-display vesicular vaccines designed to elicit strong humoral and cellular immune responses against multiple respiratory viruses and variants.
Resumen de: WO2025100882A1
The present invention discloses: a humanized ACE2-expressing transgenic mouse susceptible to SARS-CoV-2 virus infection, the mouse being obtained by applying a CRISPR system; and a method for producing same. The humanized ACE2-expressing transgenic mouse according to the present invention reflects the severity of symptoms, mortality patterns, and the like according to age, sex, viral infection dose, and the like, as observed in human COVID-19 cases, and reproduces immunopathological characteristics of SARS-CoV-2 infection in the lungs without viral replication or lesions in the brain, and thus can be effectively used to understand the pathogenesis of SARS-CoV-2 and to develop vaccines or therapeutic agents.
Resumen de: WO2025098237A1
A lyophilized RNA-LNP (e.g., mRNA-lipid nanoparticle), a method of making or using the same, such as for vaccination using an mRNA encoding an antigenic vaccine (e.g., SARS-CoV-2).
Resumen de: US2025152699A1
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
Resumen de: US2025152697A1
Disclosed herein are multi-antigenic autologous, cell-based SARS-CoV-2 vaccines comprising autologous antigen presenting cells (APCs) displaying at least two different SARS-CoV-2 antigens. These vaccines can be used to prevent SARS-CoV-2 infection or COVID-19. Further disclosed are methods for producing and using the vaccines.
Resumen de: US2025152618A1
The invention relates to sulfated chitosan derivatives of formula (I), wherein the meanings for the various substituents are as disclosed in the description, for their use in the treatment and/or prevention of a viral infection, particularly wherein the viral infection is caused by SARS-CoV-2 such as COVID-19 or RSV.
Resumen de: US2025152710A1
Provided herein are compositions with an augmented capacity to mediate ADCC. These compositions include chimeric NK cells—called “Nukes” (NK Enhancement Strategy) that express CD64 Fc receptor from an exogenous nucleic acid molecule, the NK cells having antibodies bound thereto. Methods of using these cells for treatment of HIV, cancer, SARS-COV-2, and other diseases are provided.
Resumen de: US2025152566A1
The present invention relates to a new use of an Aminopyridine, such as Pyridine-3,4-diamine, a derivative thereof and/or of a physiologically tolerable salt thereof for the prevention and/or treatment of a fatigue, which is associated with a viral infection, preferably by SARS-CoV-2. In particular for the treatment of fatigue in connection with a “post-COVID phase” and the “long COVID-19 syndrome”.
Resumen de: US2025152613A1
Provided herein are compositions for use in treatment fibrosis and in treatment of COVID-19, preferably moderate COVID-19, comprising Compound (1), or a pharmaceutically acceptable salt thereof. Also provided herein are methods for treatment of COVID-19, preferably moderate COVID-19 comprising administering to a patient in need thereof an amount of between 10 mg/day and 30 mg/day, of Compound (1).
Resumen de: US2025154204A1
The present invention relates to a novel reovirus-based vaccine platform, and confirmed that a part of the S1 gene of reovirus can be replaced with various exogenous epitope-encoding genes, and a recombinant reovirus manufactured according to the present invention not only can infect target cells and induce the expression of the epitope, but also can effectively prevent and treat diseases related to the epitope by activating the immune function of immune cells against the epitope. When using the reovirus-based vaccine platform of the present invention, vaccines containing various epitopes can be manufactured through relatively simple genetic manipulation technology, and can be administered in various ways including oral administration, so it can be utilized for the prevention and treatment of various infectious diseases including SARS-CoV-2 virus infection, and cancer.
Resumen de: US2025154230A1
The present invention relates to antibodies or antigen-binding fragments thereof against SARS-related coronavirus, pharmaceutical compositions comprising such antibodies or antigen-binding fragments thereof, a kit comprising such antibodies or antigen-binding fragments thereof, and the antibodies or antigen-binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus.
Resumen de: US2025155436A1
Liquid composition for the preparation of a biological sample for methods for assaying for the presence of SARS-COV-2 or genetic variations (mutant) of SARS-COV-2 wildtype in said sample by POC PCR comprising: • a) a chaotropic salt, preferably guanidinium thiocyanate, in a concentration ranging from 1 to 90 mM and • b) optionally one or more RNAse inhibitor.
Resumen de: US2025154231A1
The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
Resumen de: AU2023366039A1
The present invention relates generally to compositions and methods for inhibiting the replication of coronaviruses and treating diseases caused by coronavirus infection. More specifically, the invention provides nucleic acids capable of inhibiting coronavirus (e.g. SARS-CoV-2) replication and their use in treating patients infected by the virus.
Resumen de: US2025155438A1
Systems and methods are disclosed herein for pathogen detection employing a lateral flow assay (LFA) device or ELISA assay, e.g. for detecting SARS-COV-2, the virus that causes COVID-19, in a sample. The LFA device includes a nitrocellulose membrane mounted on a solid support, a sample pad for receiving a sample, a conjugate pad containing gold nanoparticles conjugated to heavy chain antibodies (HcAbs), and an absorbent pad at the end of the device.
Resumen de: EP4553084A2
The present invention relates to pharmaceutical compositions comprising an mRNA encoding an IFN-λ polypeptide for use in treating a viral-induced disorder, preferably a viral-induced respiratory disorder, such as COVID-19.
Resumen de: EP4553080A1
The invention relates to small molecule inhibitors of formula (I) targeting the nspl4 protein of SARS-CoV-2 and other coronaviruses, for use as antiviral agents directly targeting viral proteins.
Resumen de: WO2025100882A1
The present invention discloses: a humanized ACE2-expressing transgenic mouse susceptible to SARS-CoV-2 virus infection, the mouse being obtained by applying a CRISPR system; and a method for producing same. The humanized ACE2-expressing transgenic mouse according to the present invention reflects the severity of symptoms, mortality patterns, and the like according to age, sex, viral infection dose, and the like, as observed in human COVID-19 cases, and reproduces immunopathological characteristics of SARS-CoV-2 infection in the lungs without viral replication or lesions in the brain, and thus can be effectively used to understand the pathogenesis of SARS-CoV-2 and to develop vaccines or therapeutic agents.
Resumen de: KR20250064725A
본 발명은 사스 코로나바이러스 2 스파이크 항원에 특이적으로 결합하는 이뮤노글로불린 A 항체를 제조하여 이를 사스 코로나바이러스 2 검출 또는 진단 용도로 사용하거나 사스 코로나바이러스 2 중화 효과를 기반으로 사스 코로나바이러스 2 감염질환 예방 또는 치료하기 위해 사용하는 용도에 관한 것이다.
Resumen de: KR20250064724A
본 발명은 사스 코로나바이러스 2 스파이크 항원에 특이적으로 결합하는 이뮤노글로불린 A 항체를 제조하여 이를 사스 코로나바이러스 2 검출 또는 진단 용도로 사용하거나 사스 코로나바이러스 2 중화 효과를 기반으로 사스 코로나바이러스 2 감염질환 예방 또는 치료하기 위해 사용하는 용도에 관한 것이다.
Resumen de: US2025144087A1
The present application relates to the use of 3,3′-(1,3-phenylenebis(oxy))bis(1-(piperidin-1-yl)propan-2-ol (VE607) or a pharmaceutically acceptable salt thereof for the inhibition of SARS-CoV-2 and/or management of COVID-19.
Resumen de: US2025134989A1
The present invention relates to a novel vaccine composition for coronavirus infection-19 comprising a polymer-based mRNA carrier. Specifically, the present invention provides a vaccine composition comprising an mRNA carrier using a novel polymer capable of delivering a negatively charged genetic material such as mRNA, and the vaccine composition has excellent effects of enhanced in vivo immune activity such as high antibody formation ability and increased interferon-gamma production.
Resumen de: US2025145667A1
The present invention relates to peptides derived from COVID-19 virus envelope protein and spike protein. The invention further relates to polynucleotides and vectors encoding said peptides, and antibodies and chimeric antigen receptors that bind to said peptides. The invention also relates to methods of diagnosis and prediction of conditions in a subject which leverage recognition of said peptides, such as by antigen-specific T cells.
Nº publicación: AU2023375471A1 08/05/2025
Solicitante:
RES INSTITUTE AT NATIONWIDE CHILDRENS HOSPITAL
RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
Resumen de: AU2023375471A1
Provided herein is a synthetic polypeptide derived from High Mobility Group Box 1 (HMGB 1) host protein that can both disrupt bacterial biofilms and prevent Neutrophil Extracellular Trap (NET) formation. Also provided herein are methods to disrupt aberrant or excessive NET formation that are particularly well-suited to treat high-risk populations such as those infected with SARS CoV-2, sepsis, autoimmune diseases e.g., systemic lupus erythematosus, rheumatoid arthritis, Type I diabetes mellitus, small vessel vasculitis, autoinflammatory diseases e.g., gout, inflammatory bowel disease, and metabolic diseases e.g., Type 2 diabetes and obesity.
BOPI
Sede Electrónica
